The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19

Vlaar, APJ; Lim, EHT; de Bruin, S; Ruckinger, S; Pilz, K; Brouwer, MC; Guo, RF; Heunks, LMA; Busch, MH; van Paassen, P; Riedemann, NC; van de Beek, D

Vlaar, APJ (通讯作者)，Univ Amsterdam, Dept Intens Care, Amsterdam UMC, Meibergdreef 9,POB 22660, NL-1100 DD Amsterdam, Netherlands.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022; 15 (4): 854

Abstract

Recently, we reported the phase II portion of the adaptive phase II/III PANAMO trial exploring potential benefit and safety of selectively blocking C5......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索